Sanofi (SNY)
NASDAQ: SNY · Real-Time Price · USD
46.62
+0.59 (1.28%)
At close: Mar 26, 2026, 4:00 PM EDT
46.50
-0.12 (-0.26%)
After-hours: Mar 26, 2026, 7:11 PM EDT
Sanofi Revenue
In the year 2025, Sanofi had annual revenue of 46.72B EUR with 5.49% growth. Sanofi had revenue of 12.21B in the quarter ending December 31, 2025, with 6.87% growth.
Revenue (ttm)
46.72B EUR
Revenue Growth
+5.49%
P/S Ratio
2.07
Revenue / Employee
624,162 EUR
Employees
74,846
Market Cap
113.70B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 46.72B | 2.43B | 5.49% |
| Dec 31, 2024 | 44.29B | 2.67B | 6.41% |
| Dec 31, 2023 | 41.62B | 1.06B | 2.61% |
| Dec 31, 2022 | 40.56B | 1.39B | 3.54% |
| Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
| Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
| Dec 31, 2019 | 37.63B | 1.95B | 5.48% |
| Dec 31, 2018 | 35.68B | -544.00M | -1.50% |
| Dec 31, 2017 | 36.22B | 1.53B | 4.40% |
| Dec 31, 2016 | 34.70B | -165.00M | -0.47% |
| Dec 31, 2015 | 34.86B | 2.86B | 8.94% |
| Dec 31, 2014 | 32.00B | 708.00M | 2.26% |
| Dec 31, 2013 | 31.29B | -4.67B | -12.98% |
| Dec 31, 2012 | 35.96B | 899.00M | 2.56% |
| Dec 31, 2011 | 35.06B | 1.02B | 3.00% |
| Dec 31, 2010 | 34.04B | 2.80B | 8.98% |
| Dec 31, 2009 | 31.23B | 2.42B | 8.38% |
| Dec 31, 2008 | 28.82B | -390.00M | -1.34% |
| Dec 31, 2007 | 29.21B | -282.00M | -0.96% |
| Dec 31, 2006 | 29.49B | 976.00M | 3.42% |
| Dec 31, 2005 | 28.51B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Merck & Co. | 65.01B |
| Pfizer | 62.58B |
| AbbVie | 61.16B |
| AstraZeneca | 58.74B |
| Novartis AG | 56.67B |
| Novo Nordisk | 48.59B |
| Bristol-Myers Squibb Company | 48.19B |
| GSK plc | 43.97B |
SNY News
- 3 days ago - Press release: Availability of the Q1 2026 aide-mémoire - GlobeNewsWire
- 3 days ago - Press Release: Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid - GlobeNewsWire
- 3 days ago - Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment - Reuters
- 6 days ago - Sanofi launches innovation and operation centre in China - Reuters
- 8 days ago - TrumpRx lists many medicines at prices higher than paid in UK - Reuters
- 8 days ago - Mirecule Expands Strategic FSHD Collaboration with Sanofi - Business Wire
- 9 days ago - Press Release: Sanofi's venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease - GlobeNewsWire
- 9 days ago - Big drugmakers must face US overcharge claims on medications for low-income patients - Reuters